Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2013

View Archived Issues

Transmission and infectivity of emerging H7N9 influenza virus studied in animal models

Phase II results presented for ARA-290 in rheumatoid arthritis

Updated phase I/II results for daratumumab in advanced MM

DARA BioSciences grants DB-959 worldwide rights to T3D Therapeutics

FDA accepts RHB-103 NDA for review

Isotechnika Pharma receives additional funding for anti-HCV agent

Aurigene and Debiopharm nominate anticancer development candidate

Athera and Boehringer Ingelheim sign option agreement for novel preclinical antibody program

Optical probe presented for molecular imaging of bacterial infections

Clinical trial data presented for a TGFR-1 inhibitor

CollabRx forms cancer translational research collaboration with University of Chicago Medical Center

AOP Orphan spins off stake in Activartis

BELLUS Health enters agreement to acquire Thallion Pharmaceuticals

Senesco reports further results from phase Ib/IIa SNS01-T trial

Life Technologies signs agreement to develop siRNA therapeutics in China

Hangzhou Bensheng Pharmaceutical patents new agents for cancer

Sarepta Therapeutics reports updated 84-week data from phase IIb eteplirsen study

Researchers at Roche disclose new LRRK2 inhibitors

Sanofi synthesizes new CXCR3 receptor antagonists

Pfizer presents novel anti-IL-4/IL-13 bifunctional molecule with promising activity

FDA issues drug safety communication for Zyprexa Relprevv

Raptor launches Procysbi in the U.S.

Target enrollment reached in phase II trial of CCX-140 in diabetic nephropathy

FDA advisory committee sets date to review Amarin's sNDA for Vascepa

Vaxart reports phase I findings for oral H1N1 influenza vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...